LIVE

RGC

Regencell Bioscience Holdings Limited

RGC

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $4.0B

$6.44

▼ -19.80%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$5.80 - $69.00

P/E

—

Fwd P/E

—

Beta

1.64

Div Yield

0.00%

Avg Vol

162.5K

Shares Out

—

Mkt Cap

$4.0B

Price action

Price chart

Down 22.5% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

No bull reasons captured for this rating yet.

▼

Bear Case

1 risk

  • Above-average volatility (beta 1.6).

Growth

No forward estimates available

Value

Valuation data unavailable

Momentum

Falling

-73.9% over 3m

Quality

Loss-making

Weak fundamentals - proceed with caution

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

“
Q2 26 RECAP

JUN 15, 2026

Earnings recap unavailable for this period.

EPS surprise · last 4Q

0 of 4 beats

Q2 26

—

Q2 26

—

Q2 26

—

Q2 26

—

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

No analyst coverage on file for this stock yet.

View full analyst page →

vs Industry

How RGC stacks vs Drug Manufacturers - Specialty & Generic

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.

Related

Peers & themes

Peers

No peer data available.

Themes

No themes assigned.